DNA
Ginkgo Bioworks Holdings Inc
NYSE · Life Sciences Tools & Services
$10.10
+1.78 (+21.39%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 265.09M | 295.30M | 191.30M | 190.96M | 198.93M |
| Net Income | -638,687,545 | -640,323,928 | 20.53M | 22.33M | 29.70M |
| EPS | — | — | — | — | — |
| Profit Margin | -240.9% | -228.9% | 10.7% | 11.7% | 14.9% |
| Rev Growth | -10.2% | -10.2% | +6.8% | +20.3% | +23.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 152.9K | 152.9K | 35.00M | 38.12M | 33.29M |
| Total Equity | 305.83M | 305.83M | 264.00M | 235.49M | 239.75M |
| D/E Ratio | 0.00 | 0.00 | 0.13 | 0.16 | 0.14 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -579,333,367 | -613,085,327 | 38.60M | 37.06M | 33.75M |
| Free Cash Flow | — | — | 35.46M | 21.64M | 24.30M |